EHC - Arcturus wins bullish call on vaccine potential Novocure downgraded - in today's analyst action

Mario13/E+ via Getty Images Arcturus wins new bullish call at Cantor on experimental COVID-19 shot Arcturus Therapeutics (ARCT) has added ~1.3% in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting the company’s efforts to develop an mRNA-based vaccine against COVID-19. The price target of $71.00 per share implies a premium of ~97.6%. The analysts “see a clear disconnect in its current valuation.” They argue that the market for COVID-19 vaccines should persist longer than investor expectations allowing room for new players and booster shots in the near term. Following the subpar efficacy shown by CureVac’s mRNA-based COVID-19 shot, several analysts expressed concerns over the potential of other developers using the same platform to develop COVID-19 vaccines. Novocure downgraded at Mizuho after setback in liver cancer trial Novocure (NVCR) is trading flat in the pre-market after Mizuho downgraded the stock to neutral from buy following the company’s mid-stage data

For further details see:

Arcturus wins bullish call on vaccine potential, Novocure downgraded – in today's analyst action